Gf Fund Management Co. Ltd. C4 Therapeutics, Inc. Transaction History
Gf Fund Management Co. Ltd.
- $5.51 Trillion
- Q3 2025
A detailed history of Gf Fund Management Co. Ltd. transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Gf Fund Management Co. Ltd. holds 1,463 shares of CCCC stock, worth $3,613. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,463
Previous 1,751
16.45%
Holding current value
$3,613
Previous $2.5 Million
29.71%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Lynx1 Capital Management LP San Juan, PR7.1MShares$17.5 Million3.06% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.24MShares$12.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...